Johnson & Johnson (JNJ)vsLENSAR Inc (LNSR)
JNJ
Johnson & Johnson
$229.85
+1.10%
HEALTHCARE · Cap: $547.28B
LNSR
LENSAR Inc
$5.23
-2.97%
HEALTHCARE · Cap: $63.02M
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 164805% more annual revenue ($96.36B vs $58.44M). JNJ leads profitability with a 21.8% profit margin vs -58.7%. JNJ earns a higher WallStSmart Score of 59/100 (C).
JNJ
Buy59
out of 100
Grade: C
LNSR
Avoid26
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-43.5%
Fair Value
$160.13
Current Price
$229.85
$69.72 premium
Margin of Safety
+5.2%
Fair Value
$13.10
Current Price
$5.23
$7.87 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
No standout strengths identified
Areas to Watch
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -1069.0% — below average capital efficiency
Revenue declined 4.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bull Case : LNSR
LNSR has a balanced fundamental profile.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : LNSR
The primary concerns for LNSR are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
JNJ profiles as a mature stock while LNSR is a turnaround play — different risk/reward profiles.
LNSR carries more volatility with a beta of 0.98 — expect wider price swings.
JNJ is growing revenue faster at 9.9% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (59/100 vs 26/100), backed by strong 21.8% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →LENSAR Inc
HEALTHCARE · MEDICAL DEVICES · USA
LENSAR, Inc., a commercial stage medical device company, is focused on designing, developing and marketing an advanced femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. The company is headquartered in Orlando, Florida.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?